ClinicalTrials.gg
TerminatedNCT05135000Updated Jan 13, 2026Results posted

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

A Phase 2 interventional study of LTP001 and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
5th of 12
47 · median 27
Started
2022
the only one that year
Phase 2
5 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 10th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development in this indication.

Read the detailed description

This study was a non-confirmatory, randomized, participant- and investigator-blinded, placebo controlled trial evaluating the efficacy and safety of LTP001 on top of standard of care in participants with PAH.

The study included a screening period of up to 8 weeks, followed by a 24-week treatment phase with daily dosing and visits scheduled approximately every 4 weeks. One follow-up visit, which also served as the end-of-study visit, was conducted approximately 30 days after the conclusion of the treatment phase. The total duration of the study, from the beginning of the screening period to the end-of-study visit, was approximately 37 weeks.

A total of 44 participants were planned to be randomized in a 3:1 ratio to receive either LTP001 6 mg or placebo.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of PAH belonging to one of the following subgroups of the Clinical Classification Group 1 (WHO):

    • participants with idiopathic pulmonary arterial hypertension (IPAH)
    • Hereditary pulmonary arterial hypertension
    • Congenital heart disease (surgically repaired at least 12 months prior to screening)
    • drug or toxin induced (for example, anorexigen, or methamphetamine use).
  • Resting mean pulmonary arterial pressure (mPAP) > 25 mmHg; pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure \< 15 mmHg, as determined by right heart catheterization within 20 days of randomization.
  • Pulmonary Vascular Resistance > 6 Wood units (480 dynes s/cm-5), as determined by right heart catheterization within 20 days of randomization.
  • WHO Functional Class II-III
  • 6MWD must be between 150 and 550 m (inclusive). The qualifying test needs to be within 20 days of randomization. To meet the above criterion additional six minute walk test (6MWT) may be performed up to a maximum of 3 tests in total prior to dosing; the minimal time difference between two tests should be at least 4 h.

    • Standard of care therapy which is stable at least 6 weeks prior to RHC and qualifying 6MWT assessment within 20 days of randomization. Standard of care includes one or more of the following treatments:
    • prostacyclin analogues and receptor agonists (if I.V., dose adjustments must be within 20% of initial stable dose)
    • endothelin receptor antagonists (ERAs)
    • phosphodiesterase type 5 inhibitors (PDE5i)
    • soluble guanylate cyclase (sGC) stimulators

Exclusion criteria

Exclusion Criteria:

  • Participants with pulmonary hypertension (PH) in the Clinical Classification Groups 2-5 (WHO), and any PAH Group 1 subgroups not covered by Inclusion Criterion #4.
  • Participants with a history of left sided heart disease, chronic left sided heart failure, congenital or acquired valvular disease compromising left ventricular function and/or pulmonary venous hypertension or symptomatic coronary disease (non-symptomatic, revascularized coronary artery disease would be acceptable).
  • Participants with obstructive lung disease defined as: /FVC \< 60% and FEV1 \< 60% of predicted value after bronchodilator administration as well as participants with moderate or severe restrictive lung disease: Total Lung Capacity \< 70% of predicted value. Testing must have occurred within 24months of screening. If historical testing is not available, then lung function testing must be conducted during the screening period.
  • Acute or chronic impairment (other than dyspnea), which would limit the ability to comply with study requirements, including interference with physical activity and execution of study procedures such as 6MWT (e.g., angina pectoris, claudication, musculoskeletal disorder, multiple sclerosis, need for walking aids).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    LTP001

    Participants received LTP001, 6 mg, oral capsules, once daily in the morning for approximately 24 weeks

    Drug: LTP001

  • Placebo comparator
    Placebo

    Participants received LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks

    Drug: Placebo

Interventions

  • DrugLTP001

    LTP001, 6 mg, was administered orally once daily in the morning

  • DrugPlacebo

    Placebo to LTP001 was administered once daily in the morning

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25

    PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dyn.s.cm-5

    Time frame: Baseline, Week 25

Secondary outcomes

  1. Change From Baseline in Six Minute Walk Distance (6MWD)

    6MWD test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes

    Time frame: Baseline, Weeks 13 and 25

  2. Change From Baseline in Right Atrium (RA) Pressures at Week 25

    The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.

    Time frame: Baseline, Week 25

  3. Change From Baseline in Pulmonary Capillary Wedge Pressure at Week 25

    Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).

    Time frame: Baseline, Week 25

  4. Change From Baseline in Mean Pulmonary Artery Pressure at Week 25

    Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary artery pressure.

    Time frame: Baseline, Week 25

  5. Change From Baseline in Average Cardiac Output (CO) at Week 25

    Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including cardiac output (CO).

    Time frame: Baseline, Week 25

  6. Change From Baseline in Fractional Area Change (FAC)

    Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography.

    Time frame: Baseline, Weeks 5, 13, and 25

  7. Change From Baseline in Peak Velocity of Excursion (RV S')

    Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same.

    Time frame: Baseline, Weeks 5, 13, and 25

  8. Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography.

    Time frame: Baseline, Weeks 5, 13, and 25

  9. Change From Baseline in Tricuspid Annular Systolic Velocity (TASV)

    Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography.

    Time frame: Baseline, Weeks 5, 13 and 25

  10. Change From Baseline in EmPHasis-10

    emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life.

    Time frame: Baseline, Weeks 13 and 25

  11. Change From Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)

    PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts.

    Time frame: Baseline, Weeks 13 and 25

  12. Maximum Observed Blood Concentrations (Cmax) for LTP001

    The maximum (peak) observed blood drug concentration after single dose administration.

    Time frame: Day 1 and Week 25 at 15, 45, and 120 minutes post-dose

  13. Time to Reach Maximum Blood Concentrations (Tmax) of LTP001

    The time to reach maximum (peak) blood drug concentration after single dose administration.

    Time frame: Day 1 and Week 25 at 15, 45, and 120 minutes post-dose

  14. Time to Clinical Worsening

    Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six minute walk distance

    Time frame: Baseline up to approximately 30 weeks

  15. Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)

    NT-proBNP is a blood biomarker to assess right ventricular distress.

    Time frame: Baseline to Week 29

07

Results

Posted May 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneLTP001Placebo
Started3512
Completed269
Not completed93
Withdrew: Adverse event20
Withdrew: Lost to follow-up10
Withdrew: Study terminated by sponsor63

Outcome measures

PrimaryChange From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25

PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dyn.s.cm-5

Time frame:
Baseline, Week 25
Reported as:
Mean · dynes.sec.cm^-5
Change From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25
dynes.sec.cm^-5LTP001Placebo
Change From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25-1.175 ± 254.0792-49.685 ± 181.3745
SecondaryChange From Baseline in Six Minute Walk Distance (6MWD)

6MWD test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes

Time frame:
Baseline, Weeks 13 and 25
Reported as:
Mean · meters
Change From Baseline in Six Minute Walk Distance (6MWD)
metersLTP001Placebo
Week 13 n=30,103.2 ± 42.457.4 ± 29.34
Week 25 n=28,1010.4 ± 44.3621.0 ± 32.33
SecondaryChange From Baseline in Right Atrium (RA) Pressures at Week 25

The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.

Time frame:
Baseline, Week 25
Reported as:
Mean · mmHg
Change From Baseline in Right Atrium (RA) Pressures at Week 25
mmHgLTP001Placebo
Change From Baseline in Right Atrium (RA) Pressures at Week 25-0.4 ± 4.40-0.6 ± 0.73
SecondaryChange From Baseline in Pulmonary Capillary Wedge Pressure at Week 25

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).

Time frame:
Baseline, Week 25
Reported as:
Mean · mmHg
Change From Baseline in Pulmonary Capillary Wedge Pressure at Week 25
mmHgLTP001Placebo
Change From Baseline in Pulmonary Capillary Wedge Pressure at Week 250.2 ± 3.660.9 ± 2.26
SecondaryChange From Baseline in Mean Pulmonary Artery Pressure at Week 25

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary artery pressure.

Time frame:
Baseline, Week 25
Reported as:
Mean · mmHg
Change From Baseline in Mean Pulmonary Artery Pressure at Week 25
mmHgLTP001Placebo
Change From Baseline in Mean Pulmonary Artery Pressure at Week 250.4 ± 8.55-0.6 ± 5.61
SecondaryChange From Baseline in Average Cardiac Output (CO) at Week 25

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including cardiac output (CO).

Time frame:
Baseline, Week 25
Reported as:
Mean · liters per minute
Change From Baseline in Average Cardiac Output (CO) at Week 25
liters per minuteLTP001Placebo
Change From Baseline in Average Cardiac Output (CO) at Week 250.067 ± 1.07720.493 ± 0.9075
SecondaryChange From Baseline in Fractional Area Change (FAC)

Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography.

Time frame:
Baseline, Weeks 5, 13, and 25
Reported as:
Mean · percent
Change From Baseline in Fractional Area Change (FAC)
percentLTP001Placebo
Week 5 n=31,90.35 ± 6.9440.92 ± 5.622
Week 13 n=29,10-1.19 ± 6.4242.62 ± 4.417
Week 25 n=26,8-1.85 ± 5.412-1.45 ± 7.532
SecondaryChange From Baseline in Peak Velocity of Excursion (RV S')

Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same.

Time frame:
Baseline, Weeks 5, 13, and 25
Reported as:
Mean · centimeters per second
Change From Baseline in Peak Velocity of Excursion (RV S')
centimeters per secondLTP001Placebo
Week 5 n=33,110.2 ± 2.14-0.4 ± 1.50
Week 13 n=32,11-0.2 ± 2.38-0.5 ± 1.63
Week 25 n=26,90.4 ± 2.28-1.0 ± 3.00
SecondaryChange From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)

Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography.

Time frame:
Baseline, Weeks 5, 13, and 25
Reported as:
Mean · centimeters
Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)
centimetersLTP001Placebo
Week 5 n=33,110.061 ± 0.31810.042 ± 0.3383
Week 13 n=31,11-0.026 ± 0.25940.100 ± 0.2933
Week 25 n=27,90.015 ± 0.3697-0.067 ± 0.2121
SecondaryChange From Baseline in Tricuspid Annular Systolic Velocity (TASV)

Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography.

Time frame:
Baseline, Weeks 5, 13 and 25
Reported as:
Mean · centimeters per second
Change From Baseline in Tricuspid Annular Systolic Velocity (TASV)
centimeters per secondLTP001Placebo
Week 5 n=33,110.2 ± 2.14-0.4 ± 1.50
Week 13 n=32,11-0.2 ± 2.38-0.5 ± 1.63
Week 25 n=26,90.4 ± 2.28-1.0 ± 3.00
SecondaryChange From Baseline in EmPHasis-10

emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life.

Time frame:
Baseline, Weeks 13 and 25
Reported as:
Mean · score
Change From Baseline in EmPHasis-10
scoreLTP001Placebo
Week 13 n=21,9-1.490 ± 5.7108-3.622 ± 3.1712
Week 25 n=17,9-4.972 ± 8.7643-3.000 ± 4.2961
SecondaryChange From Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)

PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts.

Time frame:
Baseline, Weeks 13 and 25
Reported as:
Mean · score
Change From Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)
scoreLTP001Placebo
Week 13-1.452 ± 6.3897-3.545 ± 3.2693
Week 25-0.680 ± 5.7304-4.220 ± 6.1990
SecondaryMaximum Observed Blood Concentrations (Cmax) for LTP001

The maximum (peak) observed blood drug concentration after single dose administration.

Time frame:
Day 1 and Week 25 at 15, 45, and 120 minutes post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Blood Concentrations (Cmax) for LTP001
ng/mLLTP001Placebo
Day 138.6 ± 58.2—
Week 2539.2 ± 54.7—
SecondaryTime to Reach Maximum Blood Concentrations (Tmax) of LTP001

The time to reach maximum (peak) blood drug concentration after single dose administration.

Time frame:
Day 1 and Week 25 at 15, 45, and 120 minutes post-dose
Reported as:
Geometric mean · hours
Time to Reach Maximum Blood Concentrations (Tmax) of LTP001
hoursLTP001Placebo
Day 11.05 ± 56.6—
Week 250.979 ± 68.8—
SecondaryTime to Clinical Worsening

Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six minute walk distance

Time frame:
Baseline up to approximately 30 weeks
Reported as:
Median · days
Time to Clinical Worsening
daysLTP001Placebo
Time to Clinical Worsening211.0 (174.0 to NA)175.0 (174.0 to NA)
Statistical analysis
  • LTP001 vs Placebo · Log Rank · p = 0.6843 · Cox proportional hazard: 0.7 · 80% CI 0.2 to 2.8
SecondaryChange From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)

NT-proBNP is a blood biomarker to assess right ventricular distress.

Time frame:
Baseline to Week 29
Reported as:
Mean · picomoles per liter
Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)
picomoles per literLTP001Placebo
Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)4.609 ± 52.9047-7.918 ± 21.9731

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 241 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LTP0010/35 (0%)5/35 (14.3%)20/35 (57.1%)
Placebo0/12 (0%)2/12 (16.7%)7/12 (58.3%)
Total0/47 (0%)7/47 (14.9%)27/47 (57.4%)
Most frequent serious events
Most frequent serious events
EventLTP001PlaceboTotal
Abdominal pain upperGastrointestinal disorders0/351/121/47
Catheter site cellulitisInfections and infestations0/351/121/47
Right ventricular failureCardiac disorders1/350/121/47
DiarrhoeaGastrointestinal disorders1/350/121/47
VomitingGastrointestinal disorders1/350/121/47
COVID-19Infections and infestations1/350/121/47
Lower respiratory tract infectionInfections and infestations1/350/121/47
Bipolar disorderPsychiatric disorders1/350/121/47
HaemoptysisRespiratory, thoracic and mediastinal disorders1/350/121/47
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders1/350/121/47
Most frequent other events
Showing 10 of 28
Most frequent other events
EventLTP001PlaceboTotal
HeadacheNervous system disorders6/350/126/47
NauseaGastrointestinal disorders4/351/125/47
PalpitationsCardiac disorders3/351/124/47
InfluenzaInfections and infestations3/350/123/47
ArthralgiaMusculoskeletal and connective tissue disorders3/350/123/47
Iron deficiency anaemiaBlood and lymphatic system disorders0/351/121/47
TachycardiaCardiac disorders0/351/121/47
VomitingGastrointestinal disorders1/351/122/47
Chest discomfortGeneral disorders and administration site conditions0/351/121/47
FatigueGeneral disorders and administration site conditions2/351/123/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LTP001PlaceboTotal
Mean45.3 ± 13.0345.3 ± 13.7845.3 ± 13.07
Age, Customized
Age, Customized(Participants)LTP001PlaceboTotal
18 - <65321143
65 - <85314
Sex: Female, Male
Sex: Female, Male(Participants)LTP001PlaceboTotal
Female291039
Male628
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LTP001PlaceboTotal
White321143
American Indian or Alaska202
Asian112
08

Study locations

15 sites
  • Pulmonary Associates PA
    Mesa, Arizona 85206, United States
  • Medical Univ of South Carolina
    Charleston, South Carolina 29425, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1025ABI, Argentina
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Krakow, 31 202, Poland
  • Novartis Investigative Site
    Lodz, 91-347, Poland
  • Novartis Investigative Site
    Wroclaw, 50-556, Poland
  • Novartis Investigative Site
    Málaga, Andalusia 29010, Spain
  • Novartis Investigative Site
    Barcelona, Catalonia 08036, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Novartis Investigative Site
    London, SW3 6PH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Mar 2024, 20 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Nov 26, 2021
StartActual
Jun 30, 2022
Primary completionActual
Mar 20, 2024
CompletionActual
Apr 25, 2024
Results first posted
May 15, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05135000
Responsible party
Sponsor
First posted
Nov 26, 2021
Start date
Jun 30, 2022
Primary completion
Mar 20, 2024
Completion
Apr 25, 2024
Results posted
May 15, 2025
Last update
Jan 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTP001

Start the discussion